ES2038635T3 - Nuevas 9-desazaguaninas. - Google Patents

Nuevas 9-desazaguaninas.

Info

Publication number
ES2038635T3
ES2038635T3 ES87112339T ES87112339T ES2038635T3 ES 2038635 T3 ES2038635 T3 ES 2038635T3 ES 87112339 T ES87112339 T ES 87112339T ES 87112339 T ES87112339 T ES 87112339T ES 2038635 T3 ES2038635 T3 ES 2038635T3
Authority
ES
Spain
Prior art keywords
cells
desazaguaninas
new
derivatives
deoxyguanosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87112339T
Other languages
English (en)
Inventor
Catherine Rose Kostlan
Jagadish Chandra Sircar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2038635T3 publication Critical patent/ES2038635T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
ES87112339T 1986-08-26 1987-08-25 Nuevas 9-desazaguaninas. Expired - Lifetime ES2038635T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90048686A 1986-08-26 1986-08-26
US5941987A 1987-06-18 1987-06-18

Publications (1)

Publication Number Publication Date
ES2038635T3 true ES2038635T3 (es) 1993-08-01

Family

ID=26738724

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87112339T Expired - Lifetime ES2038635T3 (es) 1986-08-26 1987-08-25 Nuevas 9-desazaguaninas.

Country Status (16)

Country Link
EP (1) EP0260491B1 (es)
JP (2) JP2595254B2 (es)
KR (2) KR940008421B1 (es)
AT (1) ATE67203T1 (es)
AU (1) AU619724B2 (es)
CA (2) CA1293727C (es)
DE (1) DE3772913D1 (es)
DK (1) DK169705B1 (es)
ES (1) ES2038635T3 (es)
FI (1) FI85856C (es)
GR (1) GR3002697T3 (es)
IE (1) IE60433B1 (es)
NO (1) NO166485C (es)
NZ (1) NZ221463A (es)
PH (1) PH24669A (es)
PT (1) PT85582B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1294960C (en) * 1986-10-24 1992-01-28 Thomas C. Malone 7-deazaguanines as immunomodulators
EP0460116B1 (en) * 1989-02-27 1997-08-27 Biocryst Pharmaceuticals Inc. 9-substituted-8-unsubstituted-9-deazaguanines
HUT61765A (en) * 1989-10-31 1993-03-01 Biocryst Inc Process for producing purine nucleoside phosphorylase inhibitors and pharmaceutical compositions comprising same as active ingredient
US5726311A (en) * 1989-11-29 1998-03-10 Biocryst Pharmaceuticals, Inc. 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo 3,2-d!pyrimidine and pharmaceutical uses and compositions containing the same
WO1995001355A1 (en) * 1993-06-30 1995-01-12 Biocryst Pharmaceuticals, Inc. 9-deazahypoxanthines as pnp inhibitors
US5386031A (en) * 1993-12-15 1995-01-31 Warner-Lambert Company Process for the synthesis of 2-amino-3,5-dihydro-7-substituted-4H-pyrrolo[3,]pyrimidin-4-ones
AU695032B2 (en) * 1994-10-05 1998-08-06 Darwin Discovery Limited Purine and guanine compounds as inhibitors of PNP
FR2728181B1 (fr) * 1994-12-16 1997-01-31 Appryl Snc Composante catalytique pour la polymerisation des olefines, son procede de fabrication, et procede de polymerisation des olefines en presence de ladite composante catalytique
US6395733B1 (en) 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
MX9709867A (es) * 1995-06-07 1998-03-31 Pfizer Derivados de pirimidina condensados con un anillo heterociclico, composiciones que contienen los mismos, y uso de los mismos.
NZ523970A (en) * 2003-02-04 2005-02-25 Ind Res Ltd Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases
CA2540598C (en) * 2003-10-03 2013-09-24 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
NZ540160A (en) * 2005-05-20 2008-03-28 Einstein Coll Med Inhibitors of nucleoside phosphorylases
GB201417163D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
GB201417165D0 (en) * 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164556B (es) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
CA1294960C (en) * 1986-10-24 1992-01-28 Thomas C. Malone 7-deazaguanines as immunomodulators
DE3739366A1 (de) * 1987-04-10 1988-10-27 Boehringer Mannheim Gmbh Desaza-purin-nucleosid-derivate, verfahren zu deren herstellung sowie deren verwendung bei der nucleinsaeure-sequenzierung sowie als antivirale mittel

Also Published As

Publication number Publication date
AU7741687A (en) 1988-03-03
FI85856B (fi) 1992-02-28
NO166485C (no) 1991-07-31
JPH08311040A (ja) 1996-11-26
PT85582B (pt) 1990-05-31
NO873584D0 (no) 1987-08-25
CA1320203C (en) 1993-07-13
NO166485B (no) 1991-04-22
KR940008421B1 (ko) 1994-09-14
JP2650644B2 (ja) 1997-09-03
DK169705B1 (da) 1995-01-16
PH24669A (en) 1990-09-07
CA1293727C (en) 1991-12-31
FI873648A (fi) 1988-02-27
IE872070L (en) 1988-02-26
JPS6388185A (ja) 1988-04-19
PT85582A (en) 1987-09-01
DK440287D0 (da) 1987-08-24
EP0260491A1 (en) 1988-03-23
NZ221463A (en) 1990-07-26
GR3002697T3 (en) 1993-01-25
EP0260491B1 (en) 1991-09-11
FI873648A0 (fi) 1987-08-24
KR880002873A (ko) 1988-05-12
ATE67203T1 (de) 1991-09-15
DE3772913D1 (de) 1991-10-17
DK440287A (da) 1988-02-27
AU619724B2 (en) 1992-02-06
NO873584L (no) 1988-02-29
IE60433B1 (en) 1994-07-13
FI85856C (fi) 1992-06-10
KR940008848B1 (ko) 1994-09-28
JP2595254B2 (ja) 1997-04-02

Similar Documents

Publication Publication Date Title
ES2038635T3 (es) Nuevas 9-desazaguaninas.
DE69432087D1 (de) 6-Amino-purinderivate mit PDE-IV inhibierender Wirkung
DE68917012T2 (de) Immunstimulierende Guaninderivate, Zusammenstellungen und Verfahren.
DK224286D0 (da) 2',3'-dideoxy-nucleosider
AU5514190A (en) Tumor necrosis factor binding protein II, it's purification and antibodies thereto
HU0103927D0 (en) Intermediates of pyrrolo[2,3-d]pyrimidine derivatives and process for the preparation thereof
ES2063125T3 (es) Derivados de guanina inmunoestimulantes: composiciones y procedimientos.
DK322189D0 (da) Imidazo(1,2-a)-(pyridaziner eller pyraziner) til behandling af sygdomme med relation til knogletab
ES2128348T3 (es) Obtencion de composiciones para el tratamiento de alteraciones de la proliferacion celular.
FI945696A0 (fi) Laktaamidipeptidejä, joilla on HLE:a inhiboiva aktiivisuus
DK102892D0 (da) Purin-derivater, farmaceutisk praeparat omfattende forbindelserne samt forbindelser til brug som mellemprodukter
AU2527688A (en) Artificial dna base pair analogues
MY103593A (en) Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation
DK478485D0 (da) 4-oxo-pyrido(2,3-d)pyrimidin-derivater, deres fremstilling og anvendelse
DE3854158D1 (de) Nucleosid-analoge.
FI895572A0 (fi) Antivirala foereningar.